| Bioactivity | BMS-332 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.005 (DGKα) and 0.001 μM (DGKζ)[1]. |
| Target | 0.005, 0.001 μM (DGKα,DGKζ). |
| Name | BMS-332 |
| CAS | 2407892-15-1 |
| Formula | C29H27F2N5O |
| Molar Mass | 499.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wichroski M, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023;15(719):eadh1892. |